Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZX100

Peptide · developed by Capstone Therapeutics

Phase 2 Most advanced trial (none active)
CAPS Developer
2 Registered trials

What is AZX100?

AZX100 is an agent administered by intradermal injection at surgical or keloid scar sites. It has been studied for scar prevention and scar reduction, including keloid scars.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Therapy area
Dermatology, Oncology
Developer
Capstone Therapeutics (CAPS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
0HT093MD6R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00825916 Phase 2 Scar Prevention Completed CAPS
NCT00811577 Phase 2 Scar Prevention Completed CAPS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Scar PreventionScar Reduction

More from Capstone Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the CAPS page.

Follow CAPS, the company behind AZX100

See CAPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CAPS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.